Merck Ignites Firework of Research Initiatives During its 350th Anniversary Year

Funding of up to € 350,000 per research grant or up to € 30,000 per research challenge

23-May-2018 - Merck announced several research grants and challenges during the company’s 350th anniversary year in addition to already existing initiatives. The new research grants and challenges are mainly directed to scientists working in institutes, universities or start-up companies around the world. “The ...

After a good third quarter: Bayer confirms Group outlook

Net income more than doubled to EUR 642 million (plus 125.3 percent)

01-Nov-2011 - The Bayer Group achieved further sales growth and significantly increased earnings in the third quarter of 2011. “It was a good quarter for Bayer,” Management Board Chairman Dr. Marijn Dekkers said Thursday at the presentation of the interim report. He described the continuing growth momentum in ...

IMS Forecasts Global Pharmaceutical Market Growth of 5-8% Annually through 2014

Peak years of patent expiries shift growth toward generics

23-Apr-2010 - IMS Health reported that the size of the global market for pharmaceuticals is expected to grow nearly $300 billion (ex manufacturer prices) over the next five years, reaching $1.1 trillion in 2014. The 5 - 8 percent compound annual growth rate during this period reflects the impact of leading ...

AMRI Acquires Manufacturing Facilities in India

23-May-2007 - Albany Molecular Research, Inc. has signed a definitive agreement to acquire two pharmaceutical manufacturing sites, along with additional land for future expansion, in Aurangabad and Navi Mumbai, India. Under the terms of the agreement, AMRI will acquire the assets - including facilities, ...

Pfizer Says Research and Development Head John LaMattina Will Retire This Year

Company to Focus on Accelerating Development and Commercialization of Strong Early- and Mid-Stage Pipeline

22-May-2007 - Pfizer said that the President of Pfizer Global Research and Development, Dr. John LaMattina, who made many important contributions to the Company's research division throughout his 30-year career, will retire from Pfizer by the end of this year. The company will begin a search both inside and ...

Bristol-Myers Squibb Announces Discontinuation Of Development Of Investigational Oral Treatment For Type 2 Diabetes

22-May-2006 - Bristol-Myers Squibb Company announced that it has discontinued the development of muraglitazar, a dual alpha/gamma PPAR (peroxisome proliferator-activated receptor) agonist in development for type 2 diabetes and will focus its efforts on other priority portfolio projects. The U.S. Food and Drug ...

Takeda to Acquire Syrrx

09-Feb-2005 - Takeda Pharmaceutical Company Limited announced that Takeda and Syrrx Inc. agreed on February 5, 2005 (PST) to merge Syrrx, Inc. into the Takeda Group. The merger is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act and is subject to the satisfaction of other customary ...

Bayer HealthCare adapts pharmaceutical research and development to suit new business conditions

03-Dec-2004 - Bayer HealthCare (BHC) is systematically continuing the realignment of its pharmaceuticals business and has decided to adapt global pharmaceutical research and development to suit changed business conditions at the unit. This will bring the Research and Development departments in line with the ...

Merck KGaA restructured its pharmaceuticals business in Germany

02-Nov-2004 - Darmstadt - Merck KGaA has restructured its pharmaceuticals business in Germany. The business with ethicals, which formerly operated as Merck Pharma Germany as a part of Merck KGaA, has been transferred into a legally self-standing company as of November 1, 2004. The new Merck Pharma GmbH ...

Merck KGaA: Intention to close Lacassagne R&D and production site in Lyon, France

Pre-clinical research in France to be concentrated in Chilly-Mazarin

11-Jul-2003 - Merck KGaA announced today that it has decided to launch a project to restructure its pharmaceutical activities in France, including the closure of its Lacassagne research and development (R&D) and production site in Lyon. The project has been presented to employee representatives, local ...